| __timestamp | BioMarin Pharmaceutical Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 3788000000 |
| Thursday, January 1, 2015 | 152008000 | 4006000000 |
| Friday, January 1, 2016 | 209620000 | 4261000000 |
| Sunday, January 1, 2017 | 241786000 | 4371000000 |
| Monday, January 1, 2018 | 315264000 | 4853000000 |
| Tuesday, January 1, 2019 | 359466000 | 4675000000 |
| Wednesday, January 1, 2020 | 524272000 | 4572000000 |
| Friday, January 1, 2021 | 470515000 | 6601000000 |
| Saturday, January 1, 2022 | 483669000 | 5657000000 |
| Sunday, January 1, 2023 | 577065000 | 6498000000 |
| Monday, January 1, 2024 | 580235000 | 28675800000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Gilead Sciences, Inc. and BioMarin Pharmaceutical Inc. over the past decade. From 2014 to 2023, Gilead Sciences consistently outpaced BioMarin in terms of cost of revenue, with figures peaking at approximately $6.6 billion in 2021. In contrast, BioMarin's costs showed a steady increase, reaching around $577 million in 2023, marking a 345% rise from 2014. This disparity highlights Gilead's larger scale of operations and market reach. However, BioMarin's growth trajectory suggests a strategic expansion and investment in its product pipeline. As the pharmaceutical landscape continues to shift, these insights provide a window into the financial strategies of two industry leaders.
AstraZeneca PLC vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Amgen Inc. and BioMarin Pharmaceutical Inc.'s Expenses
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Zoetis Inc.
Gilead Sciences, Inc. or BioMarin Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs ADMA Biologics, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: Bio-Techne Corporation and BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Lantheus Holdings, Inc.
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Ionis Pharmaceuticals, Inc.
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Vericel Corporation's Expenses